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Abstract
Background: Multiple sclerosis (MS) is a complex disorder thought to result from an interaction between 
environmental and genetic predisposing factors which have not yet been characterised, although it is known to be 
associated with the HLA region on 6p21.32. Recently, a picture of chronic cerebrospinal venous insufficiency (CCSVI), 
consequent to stenosing venous malformation of the main extra-cranial outflow routes (VM), has been described in 
patients affected with MS, introducing an additional phenotype with possible pathogenic significance.
Methods: In order to explore the presence of copy number variations (CNVs) within the HLA locus, a custom CGH array 
was designed to cover 7 Mb of the HLA locus region (6,899,999 bp; chr6:29,900,001-36,800,000). Genomic DNA of the 
15 patients with CCSVI/VM and MS was hybridised in duplicate.
Results: In total, 322 CNVs, of which 225 were extragenic and 97 intragenic, were identified in 15 patients. 234 known 
polymorphic CNVs were detected, the majority of these being situated in non-coding or extragenic regions. The overall 
number of CNVs (both extra- and intragenic) showed a robust and significant correlation with the number of stenosing 
VMs (Spearman: r = 0.6590, p = 0.0104; linear regression analysis r = 0.6577, p = 0.0106).
The region we analysed contains 211 known genes. By using pathway analysis focused on angiogenesis and venous
development, MS, and immunity, we tentatively highlight several genes as possible susceptibility factor candidates
involved in this peculiar phenotype.
Conclusions: The CNVs contained in the HLA locus region in patients with the novel phenotype of CCSVI/VM and MS 
were mapped in detail, demonstrating a significant correlation between the number of known CNVs found in the HLA 
region and the number of CCSVI-VMs identified in patients. Pathway analysis revealed common routes of interaction of 
several of the genes involved in angiogenesis and immunity contained within this region. Despite the small sample 
size in this pilot study, it does suggest that the number of multiple polymorphic CNVs in the HLA locus deserves further 
study, owing to their possible involvement in susceptibility to this novel MS/VM plus phenotype, and perhaps even 
other types of the disease.
Background
Although multiple sclerosis is the most prevalent neuro-
logical disease in the young adult population, it is cata-
logued as a neurodegenerative disorder of unknown
aetiology [1]. Indeed, despite the proposal of inflamma-
tory, infective, and autoimmune factors as pathogenic
agents in this disease, their links with its aetiology still
remain to be elucidated [2,3]. Nonetheless, genetic stud-
ies on twins and siblings suggest that susceptibility genes
may play a role in predisposition. Indeed, candidate gene
and whole genome association studies, as well as CNV
detection on SNP-based arrays involving more than hun-
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dred thousand markers, have identified several possible
susceptibility loci in the human genome. The HLA locus
on 6p21.32 is the most confidently associated of these [4-
9], among a few others of uncertain statistical significance
[10,11]. However, even when controls are accurately ran-
domised, undetectable errors may occur, especially linked
to the geographical origins of the population and known
differences in SNPs density, depending on the various
human chromosomes or even genomic regions involved.
These errors may inflate the apparently significant differ-
ences between patients and controls (genomic inflation)
generating false positives or negatives and impeding true
recognition of the associated loci [11].
As recently reported [11], and as recommend by the
Wellcome Trust Case Control Consortium [12,13], in
order to circumvent this issue, allowing unbiased data to
be collected and replication of the associations in the
identified loci to be performed, an enormous number of
individuals have to be analysed and functional studies are
required.
All the studies into the genetics of MS performed so far
have been carried out on SNP-based arrays. However,
although SNPs do contribute to inter-individual variation
across the genome, it is now well recognised that copy
number variations (CNVs), typically ranging from 1 kb to
several Mb, also influence genetic variations and disease
susceptibility [14,8]. It is evident that CNVs account for
more nucleotide variations between individuals, and, fur-
thermore, the functional significance of these variations
might be more immediate, especially if they are located
within genes, regulatory regions or known imprinted
regions, since the possible consequence of genome imbal-
ance(s) may be more easily interpretable.
In fact, the development of robust high throughput
platforms based on comparative genomic hybridisation
(CGH) capable of identifying thousands of genomic vari-
ations has greatly improved research in this direction, as
recently demonstrated in the case of Amyotrophic Lateral
Sclerosis, a major neurodegenerative disorder in which
non-polymorphic sub-microscopic duplications and
deletions seem to be frequent in sporadic cases [15].
Recently, we described the peculiar association of
chronic cerebrospinal venous insufficiency (CCSVI) in
patients with MS [16]. CCSVI is due to stenosing venous
malformations (VM) which affect the azygous and the
jugular veins, leading to significant anomalies in cerebral
venous outflow haemodynamics [16-20]. Insufficient
cerebral venous drainage represents a mechanism poten-
tially related to increased iron stores, suggesting a patho-
genic role in the progression or even pathogenesis of this
disease [21-23].
Taking into account these premises, the aim of our
pilot study was to use an innovative CGH array to inves-
tigate the occurrence of CNVs underlying genome
imbalances in the major locus (HLA, chromosome
6p21) associated with MS. In order to sub-select a spe-
cific phenotype, we decided to recruit patients with the
"plus" phenotype (VM-CCSVI and MS). The objective
was thus to use this patient category to explore the
genomic configuration of the locus in question, thereby
seeking to identify specific regions for further investiga-
tion in a wider population.
Methods
Subjects
Fifteen patients affected by relapsing-remitting MS, diag-
nosed according to the revised McDonald criteria [24],
were recruited for the study, and their Expanded Disabil-
ity Status Scale (EDSS) [25] and Multiple Sclerosis Sever-
ity Scores (MS-SS) [26,27] were determined. In our
population, MS was associated with CCSVI venous mal-
formation, documented by a sequential Colour-Doppler/
selective venography protocol [16]. In fact, Colour Dop-
pler allowed us to determine the number of anomalous
parameters linked to CCSVI, as well as the Venous Hae-
modynamic Insufficiency Severity Score (VHISS) based
on the number of venous segments exhibiting reflux or
blocked flow [18,28]. The clinical and demographic char-
acteristics of the selected patients are given in the Addi-
tional file 1 Table S1. Informed consent was obtained
from all patients in the study.
DNA from the 15 patients was extracted by a protocol
recommended by Agilent. Highly concentrated DNA was
checked for quality using a NanoDrop (260/280 ratio =
1.8 and 260/230 ratio = 2.0), and DNA integrity was eval-
uated on agarose gel at 1% in TBE 1×.
Ethical aspects
All the experimental research that is reported in the
manuscript was performed with the approval of the
University of Ferrara Ethical Committee (Document n.
7, approved by the 27th of May 2004). The research car-
ried out on humans was in compliance with the Helsinki
Declaration http://www.wma.net/en/30publications/
10policies/b3/index.html.
Statistical Analysis
Clinical data are given as median and interquartile range.
For genotype-phenotype correlations, patients with an
overall number of CNVs within the 90th percentile were
considered. Genotype-phenotype correlations were fur-
ther analysed by means of both the Spearman rank corre-
lation test and linear regression analysis, including
evaluation of the slope and X and Y intercept, followed by
a Run Test. P values of < 0.05 were considered to be sig-
nificant.Ferlini et al. BMC Medical Genetics 2010, 11:64
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HLA locus typing
HLA-DRB1 low resolution SSP typing was performed
using commercial kits (Biotest DRB SSP Kit, Lot
B812151) in all 15 patients studied.
Microarray design, hybridization and data analysis
MS-CGH microarray design was carried out using the
web-based Agilent eArray database, version 5.4 (Agilent
Technologies, Santa Clara, CA) [29], as previously per-
formed [30]. The high density aCGH search function in
eArray was used to turn the genomic region
chr6:29,900,001-36,800,000 (March 2006, human refer-
ence sequence, NCBI Build 36.1, hg18) into a probe set by
selecting the maximum number of exonic, intronic and
intragenic 60 mer oligonucleotide CGH probes available
in the database. This set included 43102 probes that were
used to reach the array format of 4 × 44 K, creating four
identical 44 K arrays on a single slide for simultaneous
analysis of four different samples.
This platform, termed MS-CGH, is a high-density
microarray with a resolution of one probe per 160 bp
which permits rapid determination of the molecular pro-
file, identifying the presence of heterozygous or homozy-
gous copy number variations (CNVs) in the genomic
region studied.
The platform informations have been submitted to the
online data repository Gene Expression Omnibus (GEO)
[31], with accession number GPL10049.
Labelling and hybridisation were performed following
the protocols provided by Agilent (Agilent Oligonucle-
otide Array-Based CGH for Genomic DNA Analysis pro-
tocol v5.0), as described elsewhere [30]. The array was
analysed with the Agilent scanner and Feature Extraction
software (v9.1). A graphical overview was obtained and
data analysis performed using DNA Analytics software
(v4.0.36). The standard set-up of the ADM-2 statistical
analysis in this software package was employed for identi-
fication of duplications and deletions. In this set-up, and
in the case of autosomal genes, heterozygous deletions
are visualised with values of minus 1, and homozygous
deletions as minus infinite (-4 in CGH analytics). The
corresponding values for heterozygous and homozygous
duplications are plus 0.5 and plus 1, respectively. At least
4 consecutive non-overlapping probes reaching these val-
ues were required for a positive reading, together with an
absence of known SNPs in the region covered by the rele-
vant probes. All 15 patients were assessed in duplicate in
order to confirm the validity of the results.
Bioinformatics analysis of gene networks
Pathway analysis and literature mining was performed
using Pathway Studio software from Ariadne Genomics
I n c.  T h e  P a t h wa y  S t u d i o  da t a base  c o n t a i n s  m i l l i o n s  o f
regulatory and interaction events from all PubMed
abstracts, and more than 350,000 full-text articles
extracted by MedScan natural language processing tech-
nology. We employed the "Build Pathway" navigation tool
in Pathway Studio to locate literary evidence supporting
the functional association of measured genes with angio-
genesis and other processes linked to blood vessel forma-
tion, as well as to immunity and neurodegeneration.
Results
CGH-ARRAY data
Comparison with the CNV database revealed 234 known
polymorphic CNVs in the 15 patients [32], thereby con-
firmed that the HLA locus is highly polymorphic in terms
of genomic imbalance, as expected considering its known
high density of SNPs. The distribution of the CNVs
among patients, both in terms of number and density, is
shown in Figure 1.
Additional file 2 Table S2 reports all the CNVs identi-
fied in patients. An example CGH profile, corresponding
to patient PF, is shown in Additional file 3 Figure S1.
The complete CGH datasets have been submitted to
the online data repository Gene Expression Omnibus
[31], under accession number GSE20334.
Genotype-phenotype correlation: statistical analysis
CNV profiling
The number of CNVs within the 90th percentile was cor-
related with the clinical parameters of the patients (Figure
2, top panel, Additional file 1 Table S1). Fourteen patients
out of the those coded as MC (52 CNVs vs. median (IR)
23 (13) of our patient population) fell within the 90th per-
centile, and were therefore further analysed by both the
Spearman rank correlation test and linear regression
analysis (Additional file 1 Table S1). Both analyses dem-
onstrated a significant and firm correlation between the
number of CNVs and the number of stenosing venous
malformations identified (Spearman: r = 0.6590, p =
0.0104; linear regression analysis r = 0.6577, p = 0.0106)
(Figure 2 bottom panel and Figure 3).
No correlation was found between extragenic or
intragenic CNVs and the number of stenosing VMs,
respectively. No additional correlations were found
between CNVs and the number of anomalous Doppler
haemodynamic parameters, or with the VHISS. No cor-
relation was found between patient phenotypes, either
for MS and VM, and the presence of specific CNVs, CNV
haplotypes or CNV distribution.
HLA typing
Statistical analysis did not yield significant results. The
HLA-DRB1*15 class region, known to be a locus with a
major contribution to the risk of MS [33], did not strongly
occur in our population, and seemed to be unrelated to
VM clinical signs or CNV number (see Additional file 1
Table S1).Ferlini et al. BMC Medical Genetics 2010, 11:64
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Since the patients' parents were not available for study,
haplotypes and consequently allele phases could not be
established.
Pathways and gene network functional bioinformatics 
analysis
211 genes were contained within the region covered by
our CGH array.
Since the phenotype in question is characterised by
multiple sclerosis and venous malformation, we applied a
bioinformatics tool to select genes known to be involved
in angiogenesis and venous development, as well as those
linked to multiple sclerosis, immunity and neurodegener-
ation. Interestingly, several genes have been linked to
these processes. HSPA1L and HSPA1A have been corre-
lated with MS, diabetes and other immunity disorders, as
well as regulatory functions such as chromatin remodel-
ling, neuroprotection, protein folding, and regenerative-
degenerative tools like neurodegeneration, neuron toxic-
ity, cell survival, synaptic transmission and even aging
factors (senescence and telomere maintenance). The gene
GRM4 also seems to interact with many proteins linked
to MS (Figure 4A)
By focusing on specific functional pathways, for exam-
ple angiogenesis, and considering the plus phenotype of
our patients (venous malformation), we obtained a more
selective puzzle of interactions (Figure 4B). GRB2 and
HSPA1A and B genes directly act on angiogenesis, TAF11
is known to be involved in artery passage, and the E2F1
transcription factor is known to be an angiogenesis posi-
tive inducer in hepatitis and cancer. Interestingly, HLA-
DQA2 may also be implicated in angiogenesis through its
interaction with CD4.
Discussion
We recently described the CCSVI/VM phenotype associ-
ated with MS, which might participate in iron accumula-
tion in the brain, a feature known to be present in several
neurodegenerative diseases, including MS [34-36].
We designed a locus-specific CGH array in order to
explore the occurrence of CNVs in the HLA region in 15
patients with the peculiar association of CCSVI/VM and
MS phenotype.
CNVs are very abundant in the human genome, being
involved in genetic variation among populations in a sim-
ilar fashion to SNPs. Innovatively, this strategy was
adopted instead of SNP-based arrays, as the latter tend to
suffer from false positive and false negative results, in
addition to the fact that no algorithm able to unequivo-
Figure 1 Genomic distribution of the known CNVs along the HLA locus among the patients studied. In the graph the starting nucleotide for 
each CNV is reported. The HLA gene regions are highlighted in white.Ferlini et al. BMC Medical Genetics 2010, 11:64
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cally detect genomic variants of less than about 30 Kb
seems to be currently available.
However, CGH CNV detection also has inherent limi-
tations, such as probe density, and failure of hybridisation
due to the presence of SNPs in the probed region. In
addition, it is widely recommended that each novel CNV
detected by CGH be validated by an alternative method
(for example RealTime PCR or qPCR). Nevertheless,
being aware of the limit of confidence of CNV identifica-
tion by CGH, the advantage of searching for CNVs by this
technique was the possibility of directly correlating
known, validated CNVs with a potential function, which
can be related to imbalance either of specific gene(s) or of
genomic regulatory regions. In fact, the CGH approach
allows fine mapping of the identified CNVs in non-genic
regions, which may be correlated to gene regulatory func-
tions, epigenetic changes or other non-coding functions.
Indeed, the potential impact on the expression regulation
of many genes by genomic "perturbation" of one (or
more) specific genomic region(s) is intriguing, as it tenta-
tively implicates it in a variety of different complex phe-
notypes. This is the reason why this genetic model applies
very well to polygenic or multi-factorial diseases [37].
As expected, we detected a high number (234) of
known CNVs, thereby confirming that the HLA region is
very rich in structural variations, in addition to its known
high polymorphism in terms of SNPs.
Analysing the distribution of the polymorphic CNVs
identified in patients, we observed a peak of CNV num-
bers within the HLA region. Outside this specific region
however, the number of CNVs per patients remained
high, though with variable distribution.
W e  a l s o  g e n o t y p e d  t h e  H L A - D R B 1  r e g i o n  i n  o u r
patients. Statistical analysis failed to show any correlation
between the presence of the HLA-DRB1*15 allele and
VM-related clinical signs. It is well known that SNPs or
complex polymorphism density is haplotype-dependent
within the human Major Histocompatibility Complex
(MHC) [38].
However, in order to link the CNV profile and the HLA
haplotype, phasing both polymorphism types is manda-
tory. In addition, no studies have yet fully characterised
either CNVs (array-based) or SNPs in the whole genomic
region of the HLA locus. For this reason, although the
frequency of HLA-DRB1*15 in our patients' cohort seems
to be lower than the one reported in classic MS, it is not
possible to conclude whether the VM phenotype has a
distinct association with the HLA haplotype, especially
when one considers our small patient number. This
seems to be a major goal for future studies.
Interestingly, while no statistically significant associa-
tion was found between CNV type or distribution and
patient phenotype, the overall number of CNVs showed a
significant correlation with the number of stenosing mal-
formations demonstrated by venography in the extracra-
nial segments of the cerebrospinal veins. However, the
major shortcoming of this pilot study is the dimension of
the sample, which should be expanded in the future to
strengthen the as yet unconfirmed significance of our
findings. The small number of patients also affected fur-
ther sub-analysis, and both the extragenic and the
intragenic component of the CNVs were not found to be
associated to the phenotype VM. Moreover, no correla-
tions were discovered between CNVs and either the num-
ber of anomalous Doppler haemodynamic parameters or
the VHISS.
Nonetheless, the phenotype studied here, correlated
with the CNVs, is strongly associated to MS (OR 43, p <
0.0001) [16]; we speculate that the presence of VM may
contribute to the increase in iron accumulation in MS as
a pathogenic component of the disease [36]. The ham-
pered cerebral venous return consequent to extracranial
Figure 2 Stenosing venous malformation associated to MS and 
genotype-phenotype correlation. Top Panel: Exemplification of 
stenosing venous malformation associated to MS. Significant stenosis 
(arrow) of the left internal jugular vein (L IJV). B) Membranous obstruc-
tion of the outlet of the azygous vein (o AZY) into the superior vena 
cava (SVC). Bottom Panel) Linear regression analysis. A significant cor-
relation between the number of CNVs and the number of venous mal-
formations detected by means of selective venography was found (r = 
0.6577, p = 0.0106).Ferlini et al. BMC Medical Genetics 2010, 11:64
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Figure 3 Number of total (A), intragenic (B) and extragenic (C) known CNVs reported in the Database of Genomic Variants (http://projects.tcag.ca/
variation) per patient.Ferlini et al. BMC Medical Genetics 2010, 11:64
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Figure 4 Functional links of the known genes within the HLA locus networking in neurodegeneration, multiple sclerosis and immunity dis-
orders (A) and angiogenesis and venous formation pathways (B).Ferlini et al. BMC Medical Genetics 2010, 11:64
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Page 8 of 10
venous malformations is peculiar to MS, and was not
found in a miscellany of patients affected by other neuro-
degenerative disorders characterized by iron stores, such
as Parkinson's, Alzheimer's, and amyotrophic lateral scle-
rosis [16,18,36]. Theoretically, venous haemodynamic
overload may facilitate local microbleeding following
damage to vein or venule walls, becoming a distinctive
mechanism of iron deposition in MS, as we recently dem-
onstrated [36].
Taken as a whole, our data, though preliminary, suggest
that the number of polymorphic CNVs in the HLA region
did correlate with the number of VMs in our patient
cohort. Since HLA is the only region consistently associ-
ated with the disease, further studies are certainly needed
to discriminate whether the CNV findings are specific for
MS patients with venous malformations or, instead, are
similarly observed in the general MS population, regard-
less of the presence of vascular malformations.
In addition, the region studied contains 211 known
genes. Using a functional bioinformatics tool, we identi-
fied many genes interacting in both neurodegenerative
and angiogenesis circuits. Notably, HSPA1L, HSP1A and
HSP1B and the HLA-DQ2 gene network in both path-
ways. Heat-shock proteins (HSPs) represent a group of
regulatory proteins involved in a variety of processes,
including immunity and angiogenesis [39,40]. In particu-
lar HSPA1L expression is modulated by ETS1 transcrip-
tion factor and by SP100, a nuclear autoimmune antigen.
Interestingly, genes negatively regulated by ETS1 and up-
regulated by SP100, such as HSPA1L, have anti-migratory
or anti-angiogenic properties [41].
MS possesses a recognised major heritable component,
since its susceptibility is associated with the MHC class II
region, especially the HLA-DRB5*0101-HLA-
DRB1*1501-HLA-DQA1*0102-HLA-DQB1*0602 haplo-
types, which dominate genetic contribution to MS sus-
ceptibility [42]. Interestingly, HLA-DQA2 is known to be
involved in pro-inflammatory CD4(+) T-cell-mediated
a u t o i m m u n e  d i s e a s e s  s u c h  a s  M S  a n d  t y p e  1  d i a b e t e s
[43]. CD4 is also a very well known inhibitor of tumour
angiogenesis [44], thus supporting a link between the two
pathways. The interpretation of the pathway interaction
is obviously complex, but it does suggest biological and
functional links among these genes as well as, intrigu-
ingly, between angiogenesis and immunity.
Conclusions
In conclusion, we present an exploration of CNVs, identi-
fied by CGH-based methodology, in a small group of
patients with associated MS and VM. We identified 234
known CNVs, and determined that the distribution of
CNVs along the HLA region showed no peculiar topogra-
phy in the patients studied.
We found that the overall number of CNVs correlates
significantly with the venous malformative phenotype.
Consistently with the general significance of CNVs, puta-
tively involved in regulation of gene expression, this find-
ing is interesting, since it may lend weight to the
possibility that the number of structural variations within
regulatory regions represents a genomic "perturbation"
which increases susceptibility for the VM phenotype
associated with MS we describe. Obviously, confirmation
of these findings will require further studies aimed at
comparing CNV profiles in patients with the MS/VM
phenotype to those in patients presenting MS alone. This
will distinguish peculiar association(s), and potentially
disclose common/different underlying genotypes.
Regarding specific candidate genes whose expression
could potentially be disturbed by genomic imbalance or
"perturbation", pathways analysis suggested that genes
involved in angiogenesis and immunity could be proteins
worthy of further investigation.
Moreover, we hope that our custom array will be useful
for other studies, perhaps to identify structural changes
in the numerous disorders proven to be linked to the
HLA locus, including MS.
Additional material
Abbreviations
CNVs: Copy number variations; CGH: Comparative genomic hybridization;
SNPs: Single nucleotide polymorphisms; VM: Venous malformations; EDSS:
Expanded disability status scale; MS-SS: Multiple sclerosis severity score; CCSVI:
Chronic cerebrospinal venous insufficiency; VHISS: Venous haemodynamic
insufficiency severity score; VH: Venous haemodynamic criteria.
Competing interests
The authors declare that they have no competing interests.
Additional file 1 Patients Population Demographics, Clinical Parame-
ters, HLA DRB1 haplotype and CNVs number. Top table: EDSS: Expanded 
Disability Status Scale (the most widely-used disability score). MS-SS: Multi-
ple Sclerosis Severity Score (score expressing the tendency of MS to prog-
ress over the years). VH: Venous Haemodynamic Criteria (number of 
anomalous haemodynamic parameters detected by colour Doppler proto-
col), VHISS: venous haemodynamic insufficiency severity score [34]. VM: 
venous malformations (number of stenosing malformations affecting the 
cerebrospinal veins, detected by selective venography). CNVs: copy num-
ber variations. Bottom table: Summary of clinical characteristics, HLA 
DRB1*5 typing and number of CNVs of each patient studied.
Additional file 2 Genomic distribution of CNVs for each patient. 
Genomic coordinates of the known CNVs identified for each patient. Col-
umn F shows the genes where any CNVs are localized and column H the 
identification number of known CNVs as described in the database of 
Genomic Variants.
Additional file 3 CGH profile of the HLA locus. Example of a CGH profile 
in patient PF, showing duplications (red dots) and deletions (green dots)- 
Light blue bars in the lower part of the figure represent genes, while the 
known polymorphic CNVs are reported with their identification number 
(Database of Genomic Variants at http://projects.tcag.ca/variation/). Below 
is shown the map in Mbases of the locus with the distribution and density 
of CNVs.Ferlini et al. BMC Medical Genetics 2010, 11:64
http://www.biomedcentral.com/1471-2350/11/64
Page 9 of 10
Authors' contributions
MB designed and validated the custom CGH-array; MN contributed to the
patients' genomic analysis; AY performed the networking genes pathway anal-
ysis via Ariadne software; FS studied the patients from neurological aspects; AB
performed HLA genotyping, DG collected DNA samples, AL and PZ planned,
performed and interpreted the vascular studies; FG scientifically revised the
manuscript; AF designed the study and wrote the manuscript, AF and PZ
revised the manuscript and approved the final version. All the authors read and
approved the final manuscript.
Acknowledgements
We thank Hilarescere Foundation for supporting the research program on 
CCSVI and MS at the University of Ferrara, Italy. The MS-CGH array has been pat-
ented, IP number n. TO2009A000672.
Author Details
1Section of Medical Genetics, Department of Experimental and Diagnostic 
Medicine, University of Ferrara, Ferrara, Italy, 2Ariadne Genomics Inc., Rockville, 
USA, 3Department of Neurology, Bellaria Hospital, Bologna, Italy and 
4Interdepartmental Vascular Disease Center, University of Ferrara, Ferrara, Italy
References
1. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL: The genetics of multiple 
sclerosis: SNPs to pathways to pathogenesis.  Nat Rev Genet 2008, 
9:516-26.
2. Compston A, Coles A: Multiple sclerosis.  Lancet 2002, 359:1221-31.
3. Frohman EM, Racke MK, Raine CS: Multiple sclerosis--the plaque and its 
pathogenesis.  N Engl J Med 2006, 354:942-55.
4. Comabella M, Craig DW, Camiña-Tato M, Morcillo C, Lopez C, Navarro A, 
Rio J, BiomarkerMS Study Group, Montalban X, Martin R: Identification of 
a novel risk locus for multiple sclerosis at 13q31.3 by a pooled 
genome-wide scan of 500,000 single nucleotide polymorphisms.  PLoS 
One 2008, 3:e3490.
5. Ramagopalan SV, McMahon R, Dyment DA, Sadovnick AD, Ebers GC, 
Wittkowski KM: An extension to a statistical approach for family based 
association studies provides insights into genetic risk factors for 
multiple sclerosis in the HLA-DRB1 gene.  BMC Med Genet 2009, 10:10.
6. Chao MJ, Barnardo MC, Lincoln MR, Ramagopalan SV, Herrera BM, Dyment 
DA, Montpetit A, Sadovnick AD, Knight JC, Ebers GC: HLA class I alleles 
tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis 
susceptibility.  Proc Natl Acad Sci USA 2008, 105:13069-74.
7. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, 
Hillert J, Link J, Lundström W, Greiner E, Dessa Sadovnick A, Goossens D, 
Van Broeckhoven C, Del-Favero J, Ebers GC, Oostra BA, van Duijn CM, 
Hintzen RQ: Genetic variation in the KIF1B locus influences 
susceptibility to multiple sclerosis.  Nat Genet 2008, 40:1402-3.
8. Cronin S, Blauw HM, Veldink JH, van Es MA, Ophoff RA, Bradley DG, Berg 
LH van den, Hardiman O: Analysis of genome-wide copy number 
variation in Irish and Dutch ALS populations.  Hum Mol Genet 2008, 
17:3392-8.
9. Blauw HM, Veldink JH, van Es MA, van Vught PW, Saris CG, Zwaag B van 
der, Franke L, Burbach JP, Wokke JH, Ophoff RA, Berg LH van den: Copy-
number variation in sporadic amyotrophic lateral sclerosis: a genome-
wide screen.  Lancet Neurol 2008, 7:319-26.
10. International Multiple Sclerosis Genetics Consortium, Hafler DA, 
Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, 
Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, 
McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL: Risk 
alleles for multiple sclerosis identified by a genomewide study.  N Engl J 
Med 2007, 357:851-62.
11. International Multiple Sclerosis Genetics Consortium (IMSGC): Refining 
genetic associations in multiple sclerosis.  Lancet Neurol 2008, 7:567-9.
12. Wellcome Trust Case Control Consortium: Genome-wide association 
study of 14,000 cases of seven common diseases and 3,000 shared 
controls.  Nature 2007, 447:661-78.
13. Wellcome Trust Case Control Consortium: Association scan of 14,500 
nonsynonymous SNPs in four diseases identifies autoimmunity 
variants.  Nat Genet 2007, 39:1329-37.
14. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, 
Lee C: Detection of large-scale variation in the human genome.  Nat 
Genet 2004, 36:949-51.
15. Shoichet SA, Waibel S, Endruhn S, Sperfeld AD, Vorwerk B, Müller I, 
Erdogan F, Ludolph AC, Ropers HH, Ullmann R: Identification of 
candidate genes for sporadic amyotrophic lateral sclerosis by array 
comparative genomic hybridization.  Amyotroph Lateral Scler 2009, 
10:162-9.
16. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S, 
Bartolomei I, Salvi F: Chronic cerebrospinal venous insufficiency in 
patients with multiple sclerosis.  J Neurol Neurosurg Psychiatry 2009, 
80:392-9.
17. Zamboni P, Menegatti E, Bartolomei I, Galeotti R, Malagoni AM, Tacconi G, 
Salvi F: Intracranial venous haemodynamics in multiple sclerosis.  Curr 
Neurovasc Res 2007, 4:252-8.
18. Zamboni P, Menegatti E, Galeotti R, Malagoni AM, Tacconi G, Dall'Ara S, 
Bartolomei I, Salvi F: The value of cerebral Doppler venous 
haemodynamics in the assessment of multiple sclerosis.  J Neurol Sci 
2009, 282:21-7.
19. Zamboni P, Consorti G, Galeotti R, Gianesini S, Menegatti E, Tacconi G, 
Carinci F: Venous Collateral Circulation Of The Extracranial 
Cerebrospinal Outflow Routes.  Curr Neurovasc Res 2009.
20. Franceschi C: The unsolved puzzle of multiple sclerosis and venous 
function.  J Neurol Neurosurg Psychiatry 2009, 80:358.
21. Zamboni P: Iron-dependent inflammation in venous disease and 
proposed parallels in multiple sclerosis.  J R Soc Med 2006, 99:589-93.
22. Zivadinov R, Bakshi R: Role of MRI in multiple sclerosis II: brain and spinal 
cord atrophy.  Front Biosci 2004, 9:647-64.
23. Hammond KE, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D, 
Nelson SJ, Pelletier D: Quantitative in vivo magnetic resonance imaging 
of multiple sclerosis at 7 Tesla with sensitivity to iron.  Ann Neurol 2008, 
64:707-13.
24. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin 
FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, 
Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for 
multiple sclerosis: 2005 revisions to the "McDonald Criteria".  Ann 
Neurol 2005, 58:840-6.
25. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an 
expanded disability status scale (EDSS).  Neurology 1983, 33:1444-52.
26. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, 
Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, 
Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone 
MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius 
EG, Lara NT, Montalban X, Villoslada P, Silva AM, et al.: Multiple Sclerosis 
Severity Score: using disability and disease duration to rate disease 
severity.  Neurology 2005, 64:1144-51.
27. Pachner AR, Steiner I: The multiple sclerosis severity score (MSSS) 
predicts disease severity over time.  J Neurol Sci 2009, 278:66-70.
28. Menegatti E, Zamboni P: Doppler haemodynamics of cerebral venous 
return.  Curr Neurovasc Res 2008, 5:260-5.
29. Agilent Technologies eArray   [https://earray.chem.agilent.com/earray]
30. Bovolenta M, Neri M, Fini S, Fabris M, Trabanelli C, Venturoli A, Martoni E, 
Bassi E, Spitali P, Brioschi S, Falzarano MS, Rimessi P, Ciccone R, Ashton E, 
McCauley J, Yau S, Abbs S, Muntoni F, Merlini L, Gualandi F, Ferlini A: A 
novel custom high density-comparative genomic hybridization array 
detects common rearrangements as well as deep intronic mutations in 
dystrophinopathies.  BMC genomics 2008, 9:572.
31. Gene Expression Omnibus   [http://www.ncbi.nlm.nih.gov/geo/]
32. Database of Genomic Variants   [http://projects.tcag.ca/variation]
33. Lincoln MR, Ramagopalan SV, Chao MJ, Herrera BM, Deluca GC, Orton SM, 
Dyment DA, Sadovnick AD, Ebers GC: Epistasis among HLA-DRB1, HLA-
DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility.  
Proc Natl Acad Sci USA 2009, 106:7542-7.
34. Craelius W, Migdal MW, Luessenhop CP, Sugar A, Mihalakis I: Iron 
deposits surrounding multiple sclerosis plaques.  Arch Pathol Lab Med 
1982, 106:397-9.
35. Levine SM, Chakrabarty A: :The role of iron in the pathogenesis of 
experimental allergic encephalomyelitis and multiple sclerosis.  Ann N 
Y Acad Sci 2004, 1012:252-66.
36. Singh AV, Zamboni P: Anomalous Venous Blood Flow And Iron 
Deposition In Multiple Sclerosis.  J Cer Blood Flow Met 2009, 
29(12):1867-78.
Received: 1 August 2009 Accepted: 28 April 2010 
Published: 28 April 2010
This article is available from: http://www.biomedcentral.com/1471-2350/11/64 © 2010 Ferlini et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Medical Genetics 2010, 11:64Ferlini et al. BMC Medical Genetics 2010, 11:64
http://www.biomedcentral.com/1471-2350/11/64
Page 10 of 10
37. Loscalzo J, Kohane I, Barabasi AL: Human disease classification in the 
postgenomic era: a complex systems approach to human 
pathobiology.  Mol Syst Biol 2007, 3:124.
38. Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J, Forbes S, 
Gilbert JG, Halls K, Harrow JL, Hart E, Howe K, Jackson DK, Palmer S, 
Roberts AN, Sims S, Stewart CA, Traherne JA, Trevanion S, Wilming L, 
Rogers J, de Jong PJ, Elliott JF, Sawcer S, Todd JA, Trowsdale J, Beck S: 
Variation analysis and gene annotation of eight MHC haplotypes: the 
MHC Haplotype Project.  Immunogenetics 2008, 60:1-18.
39. Chaudhuri D, Suriano R, Mittelman A, Tiwari RK: Targeting the immune 
system in cancer.  Curr Pharm Biotechnol 2009, 10(2):166-84.
40. Karapanagiotou EM, Syrigos K, Saif MW: Heat shock protein inhibitors 
and vaccines as new agents in cancer treatment.  Expert Opin Investig 
Drugs 2009, 18(2):161-74.
41. Yordy JS, Moussa O, Pei H, Chaussabel D, Li R, Watson DK: SP100 inhibits 
ETS1 activity in primary endothelial cells.  Oncogene 2005, 24(5):916-31.
42. Lincoln MR, Ramagopalan SV, Chao MJ, Herrera BM, Deluca GC, Orton SM, 
Dyment DA, Sadovnick AD, Ebers GC: Epistasis among HLA-DRB1, HLA-
DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility.  
Proc Natl Acad Sci USA 2009, 106(18):7542-7.
43. Podojil JR, Miller SD: Molecular mechanisms of T-cell receptor and 
costimulatory molecule ligation/blockade in autoimmune disease 
therapy.  Immunol Rev 2009, 229(1):337-55.
44. Wieder T, Braumüller H, Kneilling M, Pichler B, Röcken M: T cell-mediated 
help against tumors.  Cell Cycle 2008, 7(19):2974-7.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/11/64/prepub
doi: 10.1186/1471-2350-11-64
Cite this article as: Ferlini et al., Custom CGH array profiling of copy number 
variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with 
venous malformations associated with multiple sclerosis BMC Medical Genet-
ics 2010, 11:64